2 Monster Stocks to Buy Without Any Hesitation

The S&P 500 has plunged 22% so far this year. Inflation fears have gripped the market. Excellent growth stocks are getting hammered. But that shouldn’t motivate investors to abandon the stock market altogether. What if I told you this was in fact the right time to invest? Market downturns pull down the stock prices of…

strong companies without any faults of their own. 

This is when investors should grab stocks of companies with great long-term prospects that are trading way below their highs. Let’s take a look at why you shouldn’t hesitate to buy these two monster stocks in the cannabis and robotic surgery space.

1. Intuitive Surgical 

The coronavirus pandemic might be weighing on Intuitive Surgical‘s (ISRG 1.98%) performance now, since its sole revenue is dependent on robotic surgeries. These are minimally evasive operations that are mostly elective medical procedures. Sales of disposable instruments and accessories used during these surgeries also add to Intuitive’s top-line.  

This dip is a temporary issue. When the pandemic wanes (which it will one day), elective procedures will be back on the table, driving Intuitive’s revenue and profits. Robotic surgery is the future of surgery, and Intuitive is dominating this market with its state-of-the-art da Vinci systems. Its recent first-quarter results are proof of that trend.

A 19% surge in the number of procedures performed worldwide drove its revenue to $1.5 billion, up from $1.3 billion in the year-ago period. It also installed an additional 311 da Vinci surgical systems in the quarter.

Intuitive also trains surgeons to use its da Vinci systems, which comes at a price for hospitals. So it is doubtful hospitals will switch quickly to any new systems even if they are cheaper, thus safeguarding Intuitive’s revenue for years to come.

For now, the company has a stable balance sheet with $8.4 billion in cash, cash equivalents, and investments. With analysts seeing a possible upside of 67% over the next 12 months, this healthcare stock is an excellent buy on the dip now.

2. Trulieve Cannabis

Florida-based Trulieve Cannabis (TCNNF 4.13%) operates 165 marijuana retail dispensaries in 11 states while dominating its home state with 114 stores.

It doesn’t come as a surprise to me to see Wall Street analysts expecting a potential upside of 244% for Trulieve’s stock over the next 12 months. With $1 billion in revenue over the trailing 12 months, Trulieve is not too far behind Curaleaf Holdings, which has been leading with the highest trailing 12-month revenue of $1.6 billion. And in Q1, Trulieve managed to outperform Curaleaf with $318 million in revenue — $5 million more than its competitor’s result.

Revenue also surged 64% year-over-year for Trulieve. However…

Continue reading at THE MOTLEY FOOL

 

Leave a Reply

Your email address will not be published.